The US presidential election slowed the flow of venture capital funding announcements during the first week of November, but the flood of new biopharmaceutical VC deals resumed during the second week of the month with several $100m-plus mega-rounds, bringing the total for the past two weeks to $1.2bn and counting.
[Sidebar#SC143262]






